Document Detail


Rivaroxaban: a review of its use for the prevention of venous thromboembolism after total hip or knee replacement surgery.
MedLine Citation:
PMID:  19719335     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Rivaroxaban (Xarelto), an oral oxazolidinone-based anticoagulant, is a potent, selective direct inhibitor of factor Xa that is used in the prevention of venous thromboembolism (VTE) in adult patients after total hip replacement (THR) or total knee replacement (TKR) surgery. In four large, clinical trials, oral rivaroxaban was more effective than subcutaneous enoxaparin in preventing postoperative VTE in patients undergoing THR or TKR surgery. Notably, the superior efficacy of rivaroxaban was achieved with a low but not significant increase in the incidence of major bleeding episodes. In addition, preliminary pharmacoeconomic analyses in several countries indicate that rivaroxaban is a cost-effective treatment strategy versus enoxaparin. Although the position of rivaroxaban relative to other therapies remains to be fully determined, it is an effective emerging option for the prevention of VTE following THR and TKR.
Authors:
Sean T Duggan; Lesley J Scott; Greg L Plosker
Related Documents :
18959355 - Dalteparin vs low-dose unfractionated heparin for prophylaxis against clinically eviden...
12424505 - Safety and efficacy of combined use of low molecular weight heparin (enoxaparin, loveno...
3710295 - Low molecular weight heparin fraction pk 10169: a new therapeutic means for anticoagula...
14715365 - A prospective registry of 5,451 patients with ultrasound-confirmed deep vein thrombosis.
22739655 - Vaginoplasty with oxidized cellulose: anatomical, functional and histological evaluation.
7528865 - Visual laser ablation of the prostate: a preliminary report.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Drugs     Volume:  69     ISSN:  0012-6667     ISO Abbreviation:  Drugs     Publication Date:  2009  
Date Detail:
Created Date:  2009-09-01     Completed Date:  2010-02-04     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7600076     Medline TA:  Drugs     Country:  New Zealand    
Other Details:
Languages:  eng     Pagination:  1829-51     Citation Subset:  IM    
Affiliation:
Wolters Kluwer Health, Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore 0754, Auckland, New Zealand. demail@adis.co.nz
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Anticoagulants / adverse effects,  economics,  pharmacology,  therapeutic use
Arthroplasty, Replacement, Hip / adverse effects*
Arthroplasty, Replacement, Knee / adverse effects*
Clinical Trials as Topic
Humans
Morpholines / adverse effects,  economics,  pharmacology*,  therapeutic use
Thiophenes / adverse effects,  economics,  pharmacology*,  therapeutic use
Venous Thromboembolism / etiology,  prevention & control*
Chemical
Reg. No./Substance:
0/Anticoagulants; 0/Morpholines; 0/Thiophenes; 0/rivaroxaban

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Salmeterol/fluticasone propionate: a review of its use in asthma.
Next Document:  Aprepitant: a review of its use in the prevention of nausea and vomiting.